Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 2

Status

Active not recruiting 9Completed 7Terminated 6Recruiting 4Withdrawn 2Not yet recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 11Gastrointestinal 11Thoracic 10Gynecologic 6Other hematologic neoplasm 5Dermatologic 5Genitourinary 4Breast 3Sarcoma 2Myeloid 2Head & Neck 2CNS 2Tumor-Agnostic 1Plasma cell 1NET 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Papillary renal cell carcinoma, sporadic 1Muscle Invasive Bladder Urothelial Carcinoma 1Hereditary leiomyomatosis and renal cell cancer 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 86pembrolizumab 76Specimen Handling 75enzalutamide 55Radiosurgery 55Radiotherapy 51Docetaxel 50Androgen Antagonists 47Gemcitabine 42Nivolumab 39darolutamide 37Prednisone 35enfortumab vedotin 32Abiraterone Acetate 31Cisplatin 30Biopsy 30Carboplatin 29cabozantinib 28Standard of Care 28apalutamide 27Pluvicto 26abiraterone 25Blood Specimen Collection 25Radiation 23Leuprolide 23Ipilimumab 22X-Rays 18relugolix 17Triptorelin Pamoate 17Surveys and Questionnaires 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Disulfides × Genitourinary × Clear all
NCT05987241 2026-05-26

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04981509 2026-05-13

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡